Compare Innodata Inc (INOD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Recursion Pharmaceuticals Inc — how do they compare? Innodata Inc trades at $62.06 (market cap $2.10B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Innodata Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Innodata Inc is more actively traded (989,493 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| INOD | RXRX | |
|---|---|---|
Market Cap | $2.10B | $2.14B |
Volume | 989,493 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $121.50 | $6.79 |
52-Week Low | $34.45 | $2.84 |
Typical Hold Time | 19 Days | 22 Days |
Enterprise Value | $1.86B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $63.42, down 4.26% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The company shows robust profitability with 42.7% gross margins and 37.7% ROE, while technical indicators suggest a bullish trend despite recent pullback. Recent developments include expansion into motion-capture AI labs and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive with analyst consensus favoring buy ratings (66.7%) and projected revenue growth to $317M in 2026. Key risks include premium valuation metrics (P/E 47.4) and customer concentration concerns, but strong cash flow generation and expanding AI service offerings provide growth catalysts for investors seeking exposure to the data engineering sector.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
